肿瘤细胞治疗研究
英文原题：Recent developments in immunotherapy for gastrointestinal tract cancers.
过去几十年见证了胃肠道（GI）肿瘤免疫治疗的兴起。
过去几十年见证了胃肠道（GI）肿瘤免疫治疗的兴起。免疫检查点抑制剂（ICIs），特别是程序性死亡蛋白1（PD-1）和PD配体-1抗体，在晚期及围手术期GI肿瘤治疗中的作用日益关键。目前，抗PD-1联合化疗被视为未经选择的晚期胃/胃食管结合部腺癌（G/GEJC）、错配修复缺陷（dMMR）/微卫星高度不稳定（MSI-H）结直肠癌（CRC）以及晚期食管癌（EC）的一线方案。此外，claudin18.2靶向CAR-T 细胞疗法在后线GI肿瘤中的令人鼓舞的表现，为实体瘤治疗中的细胞疗法带来了新希望。然而，GI肿瘤的免疫治疗仍不够精准，研究人员致力于进一步最大化和优化疗效。本综述总结了包括EC、G/GEJC和CRC在内的GI肿瘤免疫治疗的重要研究、最新进展和未来方向。
The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI) tract cancers. The role of immune checkpoint inhibitors (ICIs), particularly programmed death protein 1 (PD-1) and PD ligand-1 antibodies, has become increasingly pivotal in the treatment of advanced and perioperative GI tract cancers. Currently, anti-PD-1 plus chemotherapy is considered as first-line regimen for unselected advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJC), mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC), and advanced esophageal cancer (EC). In addition, the encouraging performance of claudin18.2-redirected chimeric antigen receptor T-cell (CAR-T) therapy in later-line GI tract cancers brings new hope for cell therapy in solid tumour treatment. Nevertheless, immunotherapy for GI tumour remains yet precise, and researchers are dedicated to further maximising and optimising the efficacy. This review summarises the important research, latest progress, and future directions of immunotherapy for GI tract cancers including EC, G/GEJC, and CRC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
